NCT03961256View on ClinicalTrials.gov

Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

October 18, 2021

Study Completion Date

October 18, 2021

Conditions
Pre Diabetes
Interventions
DRUG

Exenatide SR

Exenatide SR 2 mg subcutaneous (SQ) weekly

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER